Cargando…
Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
Aromatase is a key enzyme in the conversion of androstenedione and testosterone to oestrone and oestradiol. Intratumoral aromatase activity is expressed by around 70% of breast carcinomas, but it is not clear what effect this has on the tumour phenotype. To address this question we expressed human a...
Autores principales: | Macaulay, V. M., Nicholls, J. E., Gledhill, J., Rowlands, M. G., Dowsett, M., Ashworth, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968759/ https://www.ncbi.nlm.nih.gov/pubmed/8286214 |
Ejemplares similares
-
Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004) -
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006) -
Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: Lønning, P. E., et al.
Publicado: (1989) -
Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007) -
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
por: Bonnefoi, H. R., et al.
Publicado: (1996)